Nymox: New studies support statins for treatment, prevention of Alzheimer's

By Elaine Rigoli

Tampa, Fla., Aug. 1 - Nymox Pharmaceutical Corp. said Tuesday that the use of statin drugs, which may help treat or prevent Alzheimer's disease by reducing inflammation, have been highlighted in recent research studies.

Nymox holds patents for several statins, which are a class of cholesterol-lowering drugs.

Recent research has compared the brains of Alzheimer's patients who took statins with those who did not and found evidence that statins strikingly reduced signs of inflammation in the brain, pointing to a possible mechanism through which statin drugs might slow or prevent the progression of the disease, according to a news release.

The company said the potential for statin drugs to treat or reduce the risk of Alzheimer's has been the topic of many other research reports, epidemiological studies and reviews in leading medical and scientific journals, including Archives of Neurology, The Lancet Neurology, Neurology, and The American Journal of Medicine, as well as articles in the media, including the New York Times, Wall Street Journal, Fortune, Newsweek and Los Angeles Times.

Nymox is a pharmaceutical company based in Hasbrouck Heights, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.